Foundayo launch and higher outlook raise Eli Lilly valuation questions
Foundayo’s launch arrives amid a strong Eli Lilly stock run, with a 90-day share return of 17.91% and 81.69% total shareholder return over the past year. A valuation model adjusts growth to 18%, assumes a 30x earnings multiple in 2031, uses a 7.5% discount rate, and projects about $48 to $50 billion of earnings by then.
Coverage (4)
- Eli Lilly Slides as GLP-1 Coverage Concerns Likely Weigh on Sentiment (quiverquant.com)
- Eli Lilly Slips as Its $1.1 Trillion Valuation Cools (finance.yahoo.com)
- Eli Lilly (LLY) Is Suing Six Companies Over an Unapproved Drug—Leaving Novo Nordisk (NVO) Clear in the GLP-1 Wars (finance.yahoo.com)
- Eli Lilly (LLY) On Foundayo Launch And Higher Outlook Faces A Rich Valuation (simplywall.st)